ImmunoPRISM Trial Shows Teclistamab Improves Depth of Response and Progression-Free Survival in High-Risk Smoldering Multiple Myeloma

Dana-Farber Cancer Institute investigators presented encouraging positive results from the phase 2 ImmunoPRISM trial, a first-of-its-kind randomized trial of teclistamab, a BCMA-targeted bispecific antibody, in high-risk smoldering multiple myeloma.

By
June 14, 2026
4 min

Dana-Farber

Overview

The phase 2 ImmunoPRISM trial demonstrated that teclistamab significantly improves complete response rates and progression-free survival in patients with high-risk smoldering multiple myeloma compared to lenalidomide plus dexamethasone. Notably, 82% of patients treated with teclistamab achieved minimal residual disease negativity.

Background

High-risk smoldering multiple myeloma is a precursor to active multiple myeloma, with about 50% of patients progressing to active disease within two years. Current standard care involves observation, but recent studies suggest that early intervention may alter disease progression. The ImmunoPRISM trial is the first randomized study to evaluate a BCMA-targeted bispecific antibody in this patient population.

Data Highlights

Outcome	Teclistamab Group	Lenalidomide + Dexamethasone Group
Complete Response Rate	75.6%	0%
MRD-Negative Rate	82%	0%
Progression-Free Survival (PFS) at 23.4 months	7%	36%
Estimated 2-Year Survival	92%	51%
Very Good Partial Response or Better	87%	14%

Key Findings

Teclistamab achieved a complete response in 75.6% of patients.
82% of patients treated with teclistamab became MRD-negative.
Only 7% of teclistamab patients progressed after a median follow-up of 23.4 months.
Estimated 2-year survival was 92% for teclistamab compared to 51% for the combination therapy.
71% of teclistamab patients experienced low-grade cytokine release syndrome.

Clinical Implications

The findings suggest that teclistamab may be a more effective treatment option for patients with high-risk smoldering multiple myeloma compared to the current standard of care. Early intervention with teclistamab could potentially alter the disease trajectory and improve patient outcomes.

Conclusion

The ImmunoPRISM trial provides compelling evidence for the efficacy of teclistamab in high-risk smoldering multiple myeloma, highlighting the potential benefits of early immunologic intervention.